Intersect ENT
1555 Adams Drive
Menlo Park
California
94025
United States
Tel: 650-641-2100
Website: https://www.intersectent.com/
Email: info@intersectent.com
169 articles about Intersect ENT
-
Intersect ENT to Report First Quarter 2019 Financial Results
4/23/2019
Intersect ENT, Inc. announced that it will release first quarter financial results on May 6, 2019.
-
Intersect ENT Reports Fourth Quarter and Full Year 2018 Results
2/25/2019
Intersect ENT, Inc. reported financial results for the fourth quarter and full year ended December 31, 2018.
-
Intersect ENT to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2/12/2019
Intersect ENT, Inc. announced that management will participate in the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at the Lotte New York Palace in New York City, and will present in a session at 9:30 a.m. ET.
-
Intersect ENT to Report Fourth Quarter and Year 2018 Financial Results
2/11/2019
Intersect ENT, Inc. announced that it will release fourth quarter and year 2018 financial results on February 25, 2019.
-
Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue
1/7/2019
Revenue for the full year 2018 is expected to be in the range of $108.3 to $108.5 million, an increase of 12-13% compared to $96.3 million for 2017
-
Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon
12/17/2018
Innovative Drug-Device Combination Will Leverage Company’s Expertise in Localized Drug Delivery
-
Intersect ENT Announces Publication of Pooled Analysis of Steroid Releasing Implants in Patients Following Frontal Sinus Surgery
11/15/2018
Intersect ENT, Inc. today announced publication of a pooled analysis in the International Forum of Allergy & Rhinology, the official journal of the American Rhinologic Society, of the company’s PROPEL® Contour and PROPEL® Mini steroid releasing sinus implants showing improved outcomes of frontal sinus surgery.
-
Intersect ENT to Present at the Piper Jaffray 30th Annual Healthcare Conference
11/7/2018
Intersect ENT, Inc. today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference on November 28 at the Lotte New York Palace in New York City, and will present in a session at 10:30am ET.
-
Intersect ENT Reports Third Quarter 2018 Results
11/5/2018
Total revenue grew to $24.7 million for the third quarter 2018 compared to $22.3 million for the same period of 2017, an increase of 11%.
-
Intersect ENT Announces Executive Team Appointments
10/29/2018
Christine Kowalski Joins as Chief Operations Officer; Susan Stimson Named Chief Strategy Officer
-
Intersect ENT to Report Third Quarter 2018 Financial Results
10/17/2018
Intersect ENT, Inc. announced that it will release third quarter financial results.
-
Intersect ENT Reports Second Quarter 2018 Results
8/1/2018
Intersect ENT, Inc. is a company dedicated to improving the quality of life for patients with ear, nose and throat conditions
-
Intersect ENT to Report Second Quarter 2018 Financial Results
7/11/2018
Intersect ENT, Inc. announced that it will release financial results for its second quarter on August 1, 2018.
-
Intersect ENT to Present at William Blair & Company 38th Annual Growth Stock Conference
5/29/2018
Intersect ENT, Inc. announced that management will present at the 38th Annual William Blair Growth Stock Conference.
-
Intersect ENT Reports First Quarter 2018 Results
5/1/2018
Intersect ENT, Inc. reported financial results for the first quarter ended March 31, 2018.
-
Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
4/2/2018
New Treatment Is Clinically Proven to Reduce Polyps and Symptoms of Nasal Congestion
-
Intersect ENT Reports Fourth Quarter and Full Year 2017 Results
2/27/2018
Intersect ENT, Inc. reported financial results for the fourth quarter and year ended December 31, 2017.
-
Intersect ENT to Report Fourth Quarter and Year 2017 Financial Results
2/9/2018
Intersect ENT today announced that it will release financial results for its fourth quarter and year 2017 on February 27, 2018.
-
Intersect ENT Announces Publication of Randomized Pivotal Study of the SINUVA Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
1/23/2018
The study authors concluded that significant improvements over a range of subjective and objective endpoints, including a reduction in the need for sinus surgery by 61%, suggest that the SINUVA Sinus Implant may play an important role in management of recurrent nasal polyps.
-
Intersect ENT Reports Preliminary Q4 and Year 2017 Revenue
1/8/2018
Intersect ENT today reported preliminary unaudited revenue for the fourth quarter and year ended December 31, 2017.